MedTrace Logo

Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women

NCT05156814 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-01-06

No results posted yet for this study

Summary

To obtain new data allowing personalizing continuous hormonal therapy in perimenopausal women in Russia, the following clinical study is going to be conducted in the Russian Federation:

Conditions

Interventions

DRUG

Femoston® 1, Femoston® 2

Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)

DRUG

Duphaston

Duphaston®, 10 mg

DRUG

Klimadynon

Cimicifuga racemosa rhizomatum extract

DRUG

Divigel

Divigel, 0.1%

Sponsors & Collaborators

  • Scientific Research Institute of Public Health, Russian Federation

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2022-09-30
Completion
2023-05-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05156814 on ClinicalTrials.gov